4.33
4.33 (0%)
As of Apr 17, 2025
Vanda Pharmaceuticals Inc. [VNDA]
Source:
Company Overview
Vanda Pharmaceuticals Inc. is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
| Country | United States |
| Headquarters | washington, district of columbia |
| Phone Number | 202-734-3400 |
| Industry | manufacturing |
| CEO | Mihael H. Polymeropoulos, M.D. |
| Website | www.vandapharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $198.8 |
| Operating Profit | $-40.7 |
| Net Income | $-18.9 |
| Net Cash | $-33.5 |
Profit Ratios
| Gross Margin | $187.5 |
| Operating Margin | -20.5 |
| Profit as % of Revenues | -991.8% |
| Profit as % of Assets | -2.9% |
| Profit as % of Stockholder Equity | -3.5% |
Management Effectiveness
| Return on Equity | -3.5% |
| Return on Assets | -2.9% |
| Turnover Ratio | 30.5% |
| EBITA | $-33.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $656.2 |
| Total Liabilities | $117.7 |
| Operating Cash Flow | $-15.8 |
| Investing Cash Flow | $-17.4 |
| Financing Cash Flow | $-0.2 |
